Tel.: +33 (0)9 72 56 94 99
1

Preclinical &
drug discovery

2

Patient
Stratification

3

Biomarkers

4

Clinical
development

Patient stratification

An important step of the clinical phases, patient stratification is a strategy used to ensure your drug’s development until clinical validation. Choosing the right patients for your molecule is now possible.

PATIENT STRATIFICATION: DIFFERENTIATING RESPONDERS FROM NON-RESPONDERS IN PRE-PHASE I AND II TRIALS

With patient blood samples or tissue biopsies, our technologies are capable, in clinical phases, of predicting a patient’s reaction to a therapeutic molecule, thus identifying, pre- and post-marketing, the sub-group of patients who will respond to a given drug.

Advantages

Thanks to the technologies developed by Inoviem Scientific you can optimise your Phase II, and consequently III clinical trials, by selecting those patients identified as responders.

POST-MARKET PATIENT STRATIFICATION

Our technologies are a powerful tool to identify, prior to administration, those patients who will respond to a given treatment. They can be used by clinicians to avoid treatment of non-responder patients and by the pharmaceutical industry to develop new treatments for the group of non-responders.

Early identification of non-responder patients avoids unnecessary treatment-related side effects.

Furthermore, thanks to our technologies, you will optimise the use of your molecule and gain a new opportunity for drug development for the non-responder patients.

 

1

Preclinical &
drug discovery

2

Patient
Stratification

3

Biomarkers

4

Clinical
development